While Octapharma drug Balfaxar met the goal of its pivotal clinical trial, more deaths and blood clot problems were reported in the study drug arm versus the comparator group. The FDA is requiring a post-marketing study to further assess the drug’s risks.
Exithera Pharmaceuticals, a player in the anti-thrombosis and stroke prevention drug space, appears to be in the midst of a $9 million Series B round, according to regulatory filings. It has raised $3 million thus far, the filings said. Last we heard, the Westborough, Massachusetts company raised $2 million of a $4 million Series A […]
When it comes to managing inbound phone calls, underperformance has devastating cost implications.